These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6273564)

  • 1. Rapidity of antigenic modulation of Bordetella pertussis in modified Hornibrook medium.
    Idigbe EO; Parton R; Wardlaw AC
    J Med Microbiol; 1981 Nov; 14(4):409-18. PubMed ID: 6273564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between growth rate and loss of histamine-sensitizing factor during antigenic modulation in Bordetella pertussis.
    Idigbe EO
    Microbios; 1987; 49(199):79-89. PubMed ID: 2883559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of protective antigen, histamine-sensitising factor and envelope polypeptides in cultural variants of Bordetella pertussis.
    Wardlaw AC; Parton R; Hooker MJ
    J Med Microbiol; 1976 Feb; 9(1):89-100. PubMed ID: 57240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-envelope proteins of Bordetella pertussis.
    Parton R; Wardlaw AC
    J Med Microbiol; 1975 Feb; 8(1):47-57. PubMed ID: 165297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experimental relation between histamine-sensitizing factor and the protective antigen of Bordetella pertussis].
    Jiménez Paredes J; Ruiz Puente J; González Pacheco M
    Salud Publica Mex; 1981; 23(6):621-9. PubMed ID: 6278660
    [No Abstract]   [Full Text] [Related]  

  • 6. Structure and biological properties of solubilized envelope proteins of Bordetella pertussis.
    Robinson A; Hawkins DC
    Infect Immun; 1983 Feb; 39(2):590-8. PubMed ID: 6299946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production and properties of Bordetella pertussis heat-labile toxin.
    Livey I; Wardlaw AC
    J Med Microbiol; 1984 Feb; 17(1):91-103. PubMed ID: 6319705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of an immunoblotting method for identifying the individual proteins in the antigenic complexes of Bordetella pertussis].
    Semina IE; Iankina ZK
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Mar; (3):78-81. PubMed ID: 2568040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenylate cyclase activity during phenotypic variation of Bordetella pertussis.
    Brownlie RM; Coote JG; Parton R
    J Gen Microbiol; 1985 Jan; 131(1):27-38. PubMed ID: 2859347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experimental relation between leukocytosis and other factors of Bordetella pertussis].
    Ruiz Puente J; Rivera Rivera D; González Pacheco M
    Salud Publica Mex; 1981; 23(6):613-20. PubMed ID: 6278659
    [No Abstract]   [Full Text] [Related]  

  • 11. [A comparative analysis of the antigenic complexes isolated from synthetic and semisynthetic media for the cultivation of Bordetella pertussis].
    Semina IE; Bazhanova IG; Melikhov VI; Chechot VA; Mileĭkovskaia MM; Mertsalova NU; Shmeleva EI; Remova TN; Sukhinova EE; Ozeretskovskaia MN
    Zh Mikrobiol Epidemiol Immunobiol; 1995; (2):87-92. PubMed ID: 7653146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Bordetella pertussis suspensions by ELISA and flow cytometry.
    Jiskoot W; Westdijk J; Reubsaet CH; Beuvery EC
    Adv Exp Med Biol; 1996; 397():153-7. PubMed ID: 8718594
    [No Abstract]   [Full Text] [Related]  

  • 13. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
    Gupta RK; Saxena SN; Sharma SB; Ahuja S
    Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
    Sato Y; Sato H
    Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic and biochemical properties of the histamine-sensitizing factor from Bordetella pertussis.
    Lehrer SB; Vaughan JH; Tan EM
    J Immunol; 1975 Jan; 114(1 Pt 1):34-9. PubMed ID: 46244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant of Bordetella pertussis which lacks ability to produce filamentous hemagglutinin.
    Watanabe M; Nakase Y
    Infect Immun; 1982 Mar; 35(3):1018-23. PubMed ID: 6279510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
    Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
    Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The property of filamentous hemagglutinin of Bordetella pertussis].
    Chow MP; Lin CK; Lin JS; Chau WK; Ho CH; Chen SY; Lee SH; Yung CH
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1991 Nov; 24(4):331-8. PubMed ID: 1845342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial growth and virulence factors production by different Bordetella pertussis strains.
    Letowska I; Chodorowska M; Kaczurba E; Kuklińska D; Tyski S
    Acta Microbiol Pol; 1997; 46(1):45-55. PubMed ID: 9271847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of the lymphocytosis promoting factor-haemagglutinin of Bordetella pertussis by affinity chromatography.
    Irons LI; MacLennan AP
    Biochim Biophys Acta; 1979 Sep; 580(1):175-85. PubMed ID: 232665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.